All In Biotech

Investigational drug · Phase 3

[18F]FAPI-74 PET

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction.

Phase 3

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

2 still active

All registered trials

n/a

Any phase or sponsor naming "[18F]FAPI-74 PET"

First trial start

2023

Apr 28, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "[18F]FAPI-74 PET", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Esophageal Cancer
  • Gastric Cancer (GC)
  • Gastroesophageal Junction
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Gastrointestinal Cancers
  • Cholangiocarcinoma
  • Gastric Cancer
  • Colorectal Cancer
  • Pancreatic Ductal Adenocarcinoma
  • Hepatocellular Carcinoma

Approved drugs for the same conditions: Colorectal cancer · Pancreatic cancer · Liver cancer (hepatocellular carcinoma) · Stomach and esophageal cancer · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "[18F]FAPI-74 PET" as an intervention, largest first.

All trials
ClinicalTrials.gov returned an error (400). The numbers below may be missing or incomplete.

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Esophageal Cancer

  • Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma

  • Tegafur-gimeracil-oteracil potassiumS-1, tegafurPhase 38 trials

    Ono Pharmaceutical Co., Ltd. · Gastric Cancer, Esophageal Cancer, Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

  • AZD0901Sonesitatug vedotin, CMG901Phase 36 trials

    AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma

  • PetosemtamabMCLA-158, GEN1158Phase 35 trials

    Genmab · Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Advanced/Metastatic Solid Tumors

  • LerotinibZ650Phase 31 trial

    Sunshine Lake Pharma Co., Ltd. · Esophageal Cancer

  • SI-B003Phase 210 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck

  • TQB6411Phase 22 trials

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Advanced Lung Cancer, Esophageal Cancer

  • IMT-009Phase 21 trial

    Immunitas Therapeutics · Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.